A 5.1-month improvement in median progression-free survival — 11.5 months versus 6.4 months for pembrolizumab monotherapy — was not enough. Regeneron’s Phase 3 trial of high-dose fianlimab plus cemiplimab in first-line unresectable or metastatic melanoma missed statistical significance on its primary PFS endpoint, posting a hazard ratio of 0.845 with a p-value of 0.0627. That number sits close enough to the threshold to sting: the absolute benefit is real, but the trial was not powered or positioned to make it count where it matters most.
The design itself deserves scrutiny. With 1,546 patients randomized across four arms — two fianlimab dose levels, pembrolizumab monotherapy, and a cemiplimab monotherapy arm intended only to define component contribution — this was a large, ambitious head-to-head against the current standard of care. The low-dose arm failed more decisively, with a hazard ratio of 0.931 and p=0.4661, essentially ruling out that regimen entirely. The high-dose arm’s numeric signal is consistent with biological activity from dual LAG-3/PD-1 blockade, but a p-value that narrowly misses the line does not become approvable through sympathetic interpretation. Regulators do not grade on a curve.
What complicates the picture further is the comparator. Pembrolizumab monotherapy posted a median PFS of just 6.4 months in this trial — a relatively modest performance for a first-line melanoma population, which raises questions about whether the control arm underperformed or the patient mix introduced heterogeneity that blunted the statistical comparison. Bristol Myers Squibb’s Opdualag, a leading approved nivolumab/relatlimab combination that already demonstrated superiority over nivolumab alone, now becomes the direct test: Regeneron’s ongoing Phase 3 head-to-head between high-dose fianlimab plus cemiplimab and Opdualag will determine whether LAG-3 inhibition via a distinct antibody pairing can match or beat a leading approved dual-checkpoint regimen in this space.
The result to track from that ongoing trial is the hazard ratio against Opdualag’s established PFS benchmark — because a statistically significant win there resurrects fianlimab’s commercial and regulatory path entirely, while a second miss closes it.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
